Skip to content

The Effect of Nutritional Support by Registered Dietitians and Pharmacists in Dispensation Pharmacy For the Specific Health Guidance in Japan

The Effect of Nutritional Support by Registered Dietitians and Pharmacists in Dispensation Pharmacy For the Specific Health Guidance in Japan - The Effect of Nutritional Support by Registered Dietitians and Pharmacists in Dispensation Pharmacy For the Specific Health Guidance in Japan

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000041166
Enrollment
15
Registered
2020-09-01
Start date
2020-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic syndrome

Interventions

A dietitian will provide low-carbohydrate diet interventions for 5 to 30 minutes each time in a dispensing pharmacy, about once a week for 12 weeks.

Sponsors

Kitasato Institute Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Abdominal girth >= 85cm (male) or 90 cm (female) or BMI >= 25 2)Fasting blood glucose level >= 100 mg/dl or HbA1c >=5.6% 3)Systolic blood pressure >= 130 mmHg or diastolic blood pressure >= 85 mmHg 4)Fasting triglyceride level >= 150 mg/dl or HDL-C < 40 mg/dl

Exclusion criteria

Exclusion criteria: 1)Diabetic patients receiving more than 1/2 of the maximum insurable dose of sulfonylurea 2)Diabetic patients receiving more than 25 units of injectable insulin per day 3)Type 1 diabetics or diabetics with insulin dependent conditions patients 4)Patients who started a new or increased dose of diabetes medication within 3 months of obtaining consent 5)Patients who started a new or increased dose of hypertension medication within 3 months of obtaining consent 6)Patients who started a new or increased dose of a hyperlipidemic drug within 3 months of obtaining consent 7)Patients who are pregnant, lactating, possibly pregnant, or expecting 8)Patients who have a malignancy or a history of malignant treatment within 12 months of obtaining consent 9)Other patients who are deemed inappropriate by the principal investigator

Design outcomes

Primary

MeasureTime frame
Risk values for developing diabetes by using the diabetes risk prediction tool(J-ECOH study)

Countries

Japan

Contacts

Public ContactYoshihiro Ishihara

Flexible inc CEO

ishihara@flexibleinc.jp0364553055

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026